ACT for Type 2 Diabetes in India: Addressing Complications at the Cellular Level | ALIV

Medically Reviewed by Dr. Sunita Tandulwadkar | Written by ALIV

Type 2 diabetes is India's fastest-growing chronic disease — affecting an estimated 77 million adults and producing, over years of poorly controlled glycaemia, a range of serious complications: peripheral neuropathy (nerve damage producing numbness, tingling, and pain in the feet and hands), nephropathy (kidney damage), retinopathy (eye damage), impaired wound healing, and fatigue driven by chronic inflammatory burden and mitochondrial dysfunction in key organs. ALIV's ACT programme for type 2 diabetes targets these complications through paracrine regenerative support — not by replacing insulin or reversing the metabolic disease itself, but by addressing the cellular damage that sustained hyperglycaemia produces.

The Cellular Mechanism of Diabetic Complications

Sustained elevated blood glucose damages cells and tissues through several pathways: advanced glycation end products (AGEs) that cross-link proteins and disrupt cellular function; oxidative stress from the metabolic burden of glucose toxicity; and chronic low-grade inflammation driven by elevated IL-1β, TNF-α, and NF-κB activation in multiple organ systems. Together, these pathways produce the microvascular and neuropathic damage of diabetes complications. Importantly, these damage mechanisms continue even when blood glucose is subsequently well-controlled — explaining why diabetic complications can progress despite HbA1c improvement. ACT's anti-inflammatory paracrine signals, growth factors supporting cellular regeneration (VEGF for microvascular repair, IGF-1 for metabolic cellular support, HGF for tissue regeneration), and antioxidant cellular environment target these mechanisms directly.

Specific Applications in Diabetic Complications

Diabetic peripheral neuropathy: Neurotrophic factors in ACT preparations (BDNF, NGF, IGF-1) support peripheral nerve survival and regeneration. Clinical goals are reduction in neuropathic pain (burning, tingling), improved nerve conduction where meaningful recovery capacity exists, and stabilisation of further neuropathic progression. Response in neuropathy is typically slow — six to twelve months for meaningful clinical change. Impaired wound healing: VEGF and PDGF in ACT preparations directly support angiogenesis (new blood vessel formation) and fibroblast activation — the critical rate-limiting steps in diabetic wound healing that are suppressed by the chronic inflammatory and vasculopathic environment of diabetes. ACT as an adjunct to wound care in diabetic foot ulcers that are healing poorly on standard management is a specific and clinically relevant application. General metabolic support: MSC paracrine signals have been shown in experimental and early clinical models to improve insulin sensitivity and reduce the pancreatic beta-cell inflammatory burden — potentially supporting better glycaemic control as an additional benefit. See: full ACT patient guide.

Should I continue my diabetes medications during ACT treatment?

Yes — absolutely. ACT does not replace metformin, GLP-1 agonists, insulin, or any other prescribed diabetes management. The clinical goal of ACT in type 2 diabetes is to address complications and improve the cellular environment — not to manage blood glucose directly. Changing diabetes medications in anticipation of ACT "taking over" glucose management is clinically inappropriate. ALIV's clinical team works closely with patients' endocrinologists and diabetologists to ensure integrated care.

What are realistic expectations for ACT in type 2 diabetes?

ACT for diabetes is primarily a complication-management therapy. Patients with active peripheral neuropathy, impaired wound healing, or significant fatigue from diabetic cellular dysfunction are the primary beneficiaries. Patients seeking ACT to reverse their diabetes or eliminate insulin requirements are not appropriate candidates. Realistic expectations include: stabilisation of neuropathic progression, reduction in neuropathic pain over six to twelve months, improved wound healing where vascular and neural supply is not entirely lost, and general improvement in energy and inflammatory burden. See our ACT results timeline guide for detailed expectations.

How does ALIV assess diabetic patients for ACT suitability?

ALIV's pre-ACT assessment for diabetic patients includes review of current glycaemic management and specific guidance for procedure day. Patients on insulin require specific dietary and insulin timing instructions on the harvest day — these are provided by the clinical team at the pre-ACT consultation. Blood glucose is monitored during the procedure day and the clinical team is equipped to manage any glycaemic excursion. Patients should bring their glucose monitoring device and inform the team of their current glycaemic range and any recent hypoglycaemic episodes.

Will ACT help with diabetic foot problems?

For diabetic patients with peripheral neuropathy affecting the feet and impaired wound healing, ACT can be a meaningful adjunctive intervention alongside meticulous wound care, appropriate offloading, infection management, and vascular assessment. The growth factor profile of ACT preparations directly targets the vascular and neurotrophic deficits driving diabetic foot pathology. This is not a replacement for standard wound care — it is an adjunct that addresses the underlying biological environment in which wound healing is occurring. Patients with active infection in a diabetic foot wound should have the infection controlled before ACT is considered. Learn more about ACT for diabetic foot in India.

Medically Reviewed by Dr. Sunita Tandulwadkar. This article is for informational purposes only and does not constitute medical advice. Therapies offered by ALIV are proprietary, experimental protocols and results vary by individual.